Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

04 June 2016 : Clinical Research  

A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia

Yanwei CaoABCDEF, Yonghua WangABCDEF, Lei GuoBCDE, Xuecheng YangBCDE, Tao ChenBCDE, Haitao NiuBDEG

DOI: 10.12659/MSM.896283

Med Sci Monit 2016; 22:1895-1902

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH), a common disease in men over age 50 years, often causes bladder outlet obstruction and lower urinary tract symptoms (LUTS). Alpha blockers in combination with muscarinic receptor antagonists may have the potential to improve symptoms. This study aimed to assess the efficacy and safety of doxazosin or tamsulosin combined with tolterodine extend release (ER) in patients with BPH and LUTS.

MATERIAL AND METHODS: In a prospective, randomized, open-label study (ChiCTR-IPR-15005763), 220 consecutive men with BPH and LUTS were allocated to receive doxazosin 4 mg and tolterodine ER 4 mg per day (doxazosin group) or tamsulosin 0.2 mg and tolterodine ER 4 mg per day (tamsulosin group). Treatment lasted 12 weeks. The primary endpoint was the international prostatic symptom score (IPSS). Secondary endpoints were quality of life (QoL) and maximum flow rate (Qmax), which were evaluated at 0, 6, and 12 weeks, and urodynamic parameters assessed at 0 and 12 weeks.

RESULTS: A total of 192 patients completed the trial. Baseline measurements showed no differences between the groups. After 6 weeks, IPSS improved in both groups and QoL was significantly better in the doxazosin group (P=0.01). After 12 weeks, Qmax, IPSS, QoL, intravesical pressure (Pves), and bladder compliance (BC) in the doxazosin group were significantly better than in the tamsulosin group (P=0.03, P<0.001, P<0.001, P=0.027, and P=0.044, respectively).

CONCLUSIONS: Administration of alpha blockers combined with muscarinic receptor blocker for 12 weeks improved LUTS in men with BPH.

Keywords: Adrenergic alpha-Antagonists - therapeutic use, Doxazosin - therapeutic use, Drug Therapy, Combination, Prospective Studies, Prostatic Hyperplasia - drug therapy, Quality of Life, Sulfonamides - therapeutic use, Tolterodine Tartrate - therapeutic use

Add Comment 0 Comments

Editorial

01 November 2024 : Editorial  

Editorial: Artificial Intelligence (AI), Digital Image Analysis, and the Future of Cancer Diagnosis and Prognosis

Dinah V. Parums

DOI: 10.12659/MSM.947038

Med Sci Monit 2024; 30:e947038

0:00

In Press

Database Analysis  

Impact of Tigecycline on Coagulation in Severe Infections and Effect of Vitamin K1 Intervention: A Retrospe...

Med Sci Monit In Press; DOI: 10.12659/MSM.944778  

Animal Research  

Impact of Fresh Khat Extract on Proinflammatory Cytokines and Hepatic and Renal Responses

Med Sci Monit In Press; DOI: 10.12659/MSM.946108  

Review article  

Epigenetic and Immune Mechanisms Linking Breastfeeding to Lower Breast Cancer Rates

Med Sci Monit In Press; DOI: 10.12659/MSM.945451  

Clinical Research  

Comprehensive Analysis of Immune Infiltration and Key Genes in Peri-Implantitis Using Bioinformatics and Mo...

Med Sci Monit In Press; DOI: 10.12659/MSM.941870  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,085,453

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research   1,907,170

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   695,059

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

07 Jan 2022 : Meta-Analysis   259,783

Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...

DOI :10.12659/MSM.935074

Med Sci Monit 2022; 28:e935074

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750